Finsbury Glover Hering Completes Merger and Buy-in and Announces Global Executive Leadership
11.1.2021 14:00:00 EET | Business Wire | Press release
Following their announcement on 7 July 2020, Finsbury, The Glover Park Group (GPG) and Hering Schuppener have completed their merger and management buy-in of 49.99 per cent of the combined business. The merger will create a pre-eminent global strategic communications and public affairs consultancy, operating from 18 offices with almost 700 consultants. WPP will remain a 50.01 per cent investor and Mark Read, CEO of WPP, will join the Board.
Over the past six months, the three firms have worked to integrate their operations and today announce global executive leadership teams, who will be charged with overseeing operations and driving growth across their regions.
Alexander Geiser serves as Global CEO and Regional CEO for Europe, Mike Feldman and Winnie Lerner as Regional Co-CEOs for North America and Faeth Birch as Regional CEO for the United Kingdom, Middle East and Asia. As previously announced, Carter Eskew and Roland Rudd are Co-Chairmen of the firm.
The merger of the three firms comes at a time when companies and organizations are navigating through an increasingly complex operating environment and balancing challenging social, political and economic dynamics. Finsbury Glover Hering will be a trusted partner to its clients, supporting their efforts to manage through these cross-currents and achieve their business goals. The combined entity will offer clients new reach across stakeholder audiences and geographies, allowing for fully-integrated communications campaigns.
Roland Rudd, Co-Chairman, said, “This is a great moment for Finsbury Glover Hering, we are all energised and excited by the opportunity to create a very special, owner-led firm and be an even better partner to our existing and new clients. We thank them for their support.”
“I am proud to have such a talented team leading our people across the world. I have worked with both Mike and Winnie for decades and have collaborated with Alex and Faeth on global projects over the years. The future of our global firm could not be in better hands,” said Carter Eskew, Co-Chairman.
Alexander Geiser, CEO, added: “We have received overwhelmingly positive feedback from clients and employees alike for this step. Both externally and internally, many have already experienced us as one firm. Now it has really become one firm – with a global brand, balance sheet and governance.”
About Finsbury Glover Hering
Finsbury Glover Hering is a new pre-eminent global strategic communications advisory firm, headquartered in New York City with almost 700 multidisciplinary experts across the world’s major financial, government, business and cultural centers. The company was formed through the merger of the leading strategic communications consultancies Finsbury, The Glover Park Group (GPG) and Hering Schuppener. The firm provides combined support in Business Transformation, Corporate Reputation & Leadership Strategies, Crisis & Issues Management, Government Relations & Policy and Advocacy as well as Transaction & Financial Communications, supported by research & insights, digital strategy, design and creative solutions.
Finsbury Glover Hering serves its global client base from offices in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Munich, New York, Riyadh, Shanghai, Singapore, Tokyo and Washington D.C.
Find more information visit www.fgh.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005217/en/
Contact information
Press contacts
USA
Ben Waldron
ben.waldron@fgh.com
+1 347 622 3740
UK
Dorothy Burwell
dorothy@fgh.com
+44 (20) 7251 3801
Europe
Dirk von Manikowsky
dirk.vonmanikowsky@fgh.com
+49 (211) 430 79 265
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom